In line with our transition from a CRO to a biotechnology company, Liverpool ChiroChem Ltd has officially been renamed to ‘LCC Therapeutics Ltd’. LCC Therapeutics is developing best-in-class small molecule therapeutics. We have built and validated our platform over 10 years as a fee-for service business (Liverpool ChiroChem), via successful delivery across multiple target classes, including kinases, GPCRs, DUBs, and now mRNA small molecule targets. Our best-in-class chemistry platform is superior by intelligence of design. It offers:
- Increased novelty (which gives us freedom to operate)
- Increased diversity (which provides better sampling of chemical space and increased likelihood of successfully finding a hit)
- Increased 3D-character & assured chiral purity (which leads to more specific/selective protein-ligand interactions and less off-target/side effects) and better drug-like properties (e.g., solubility, permeability, bioavailability).
The market needs quality, and that’s where LCC Therapeutics fits in. 